Premaitha Health Plc, which has a prenatal test for assessing the risk of Down’s syndrome and other genetic defects, has raised £8 million from a placement of new shares on the AIM section of the London Stock Exchange.
4SC AG has secured funding for the further clinical development of its histone-deacetylase (HDAC) inhibitor resminostat enabling it to take the compound through a Phase 2 and pre-registration trial in patients with cutaneous T cell lymphoma (CTCL).
Denmark-based Bavarian Nordic A/S has received a $133 million order for the supply of its Imvamune smallpox vaccine to the US government for stockpiling in case of a biological emergency. The new order is an extension of an existing contract.
Vertex Pharmaceuticals Inc has won approval in the US for a second drug to treat cystic fibrosis, this time for a treatment targeting the F508del mutation, the most common cause of the disease. Called Orkambi (lumacaftor/ivacaftor), the drug is indicated for patients who have two copies of the mutation.
A public US share offering of Pieris Pharmaceuticals Inc (formerly Pieris AG) has raised a gross amount of $25 million following the sale of 9,090,909 new shares to international investors. The net proceeds are expected to be $22.7 million.
Biogen Inc has thrown its weight behind gene therapy with a decision to invest potentially $1 billion for rights to an early clinical, and a host of pre-clinical and discovery gene therapy assets directed at ophthalmic diseases and one non-ophthalmic condition.
The cell therapy company Kiadis Pharma BV started trading on the Euronext stock exchange in Amsterdam and Brussels on 2 July after an initial public offering that raised €32.7 million. At the opening, the shares traded at €12.50. This compares with an offer price of €11 to €13.75 per share.
Novo Nordisk A/S has become the latest producer of a diabetes medicine to stop supplying the German market following a disagreement over pricing. Novo will cease supplying Tresiba (insulin degludec) in Germany after 30 September 2015.
Abingdon Health Ltd, a UK-based diagnostic company, has obtained £3 million from a syndicate of investors led by Imperial Innovations Group Plc to support the commercialisation of its recently launched device to detect multiple myeloma.
DBV Technologies SA, a French company which is developing a patch for peanut and milk allergies, has announced plans for a second US share offering in less than a year to support development of its technology.